Is Biora Therapeutics, Inc. overvalued or undervalued?

As of 15 August 2022, the valuation grade for Biora Therapeutics, Inc. moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, as evidenced by its extreme EV to Sales ratio of 36.76 and negative metrics across key financial ratios, including a Price to Book Value of -0.01 and an EV to EBITDA of -0.61.
In comparison to its peers, Biora's valuation metrics are starkly unfavorable; for instance, GeneDx Holdings Corp. has a P/E ratio of -63.58 and an EV to EBITDA of 166.66, while Personalis, Inc. shows a P/E of -6.55 and an EV to EBITDA of -6.66. The company's stock has underperformed significantly against the S&P 500, with a one-year return of -97.99% compared to the index's 10.26%. Overall, Biora Therapeutics, Inc. presents a concerning investment outlook based on its current financial ratios and peer comparisons.